




DOCKET NO.: I0248.70023US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Adams et al.
Serial No.: 10/616,694
Confirmation No.: 1643
Filed: July 9, 2003
For: METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE
BOROPROLINE COMPOUNDS
Examiner: David Lukton
Art Unit: 1654

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 16th day of May, 2006.


Emily E. Lukauskas

MAIL STOP AMENDMENT

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

- Information Disclosure Statement
- PTO Form 1449 with cited references
- Copy of Invitation to Pay Additional Fees dated January 10, 2005
- Copy of International Search Report dated May 18, 2005
- Copy of International Preliminary Examination Report dated October 25, 2005
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check in the amount of \$180 is enclosed to cover the filing fee. If the fee is insufficient, the balance may be charged to Deposit Account 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

By:


Maria A. Trevisan, Reg. No.: 48,207
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: I0248.70023US00

Date: May 16, 2006

xNDDx




DOCKET NO.: I0248.70023US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Adams et al.
Serial No.: 10/616,694
Confirmation No.: 1643
Filed: July 9, 2003
For: METHODS AND COMPOSITIONS RELATING TO
ISOLEUCINE BOROPROLINE COMPOUNDS
Examiner: David Lukton
Art Unit: 1654

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 16th day of May, 2006.


Emily E. Zukauskas

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed more than three months after the filing date of this application and after the mailing date of the first Office action, but before the mailing date of any final action under 37 C.F.R. §1.113, a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in this application.

The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the enclosed search report or other communication from a corresponding International or Foreign National Application.

<u>Serial No.</u>	<u>Mailing Date</u>	<u>Type(s) of Communication</u>	<u>Docket No.</u>
PCT/US03/21405	January 10, 2005	Invitation to Pay Additional Fees	I0248.70023WO00
PCT/US03/21405	May 18, 2005	International Search Report	I0248.70023WO00
PCT/US03/21405	October 25, 2005	International Preliminary Examination Report	I0248.70023WO00

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

Serial No.: 10/616,694
Conf. No.: 1643

- 3 -

Art Unit: 1654

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By:



Maria A. Trevisan, Reg. No. 48,207
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: I0248.70023US00

Date: May 16, 2006

xNDDx

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: 10/616,694	ATTY. DOCKET NO.: I0248.70023US00
		FILING DATE: July 9, 2003	CONFIRMATION NO.: 1643
		APPLICANT: Adams et al.	
		GROUP ART UNIT: 1654	EXAMINER: David Lukton
Sheet MAY 18 2006 1 of 4			

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		4,652,552		Kettner et al.	03-24-1987
		4,963,655		Kinder et al.	10-16-1990
		5,093,477		Mölling et al.	03-03-1992
		5,187,157		Kettner et al.	02-16-1993
		5,242,904		Kettner et al.	09-07-1993
		5,250,720		Kettner et al.	10-05-1993
		6,201,132	B1	Jenkins et al.	03-13-2001
		6,890,904	B1	Wallner et al.	05-10-2005
		6,949,514		Wallner et al.	09-27-2005
		2003-0220267	A1	Matteson et al.	11-27-2003
		2004-0229848	A1	Demuth et al.	11-18-2004
		2005-0008644	A1	Huber et al.	01-13-2005
		2005-0084490	A1	Adams et al.	04-21-2005
		2005-0171025	A1	Von Hoersten et al.	08-04-2005

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
		AU	729369		Ludwig Institute for Cancer Research	02-01-2001	
		DD	158109		Martin-Luther-Universitaet Halle Wittenberg	12-29-1982	Y-Abstract
		DD	294711	A5	Martin-Luther-Universitaet Halle Wittenberg	10-10-1991	Y-Abstract
		DD	296075	A5	Martin-Luther-Universitaet Halle Wittenberg	11-21-1991	Y-Abstract
		EP	0 356 223	A2	Merck and Co., Inc.	02-26-1990	
		EP	0 420 913	A1	Cell Med, Inc.	12-28-1989	
		EP	0 471 651	A2	Sandoz Ltd.	02-19-1992	
		EP	0 481 311	A2	Merck Patent Gesellschaft	10-18-1990	Y-Abstract

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/616,694	ATTY. DOCKET NO.: I0248.70023US00		
				FILING DATE: July 9, 2003	CONFIRMATION NO.: 1643		
				APPLICANT: Adams et al.			
				GROUP ART UNIT: 1654	EXAMINER: David Lukton		
Sheet	2	of	4				

	WO	94/20526	A1	Sandoz-Erfindungen Verwaltungsgesellschaft M.B.H.	09-15-1994	
	WO	94/28915	A1	Institut Pasteur	12-22-1994	Y-Abstract
	WO	94/29335	A1	Astra Aktiebolag	12-22-1994	
	WO	95/12618	A1	Eurogenetics N.V.	05-11-1995	
	WO	95/29190	A1	Institut Pasteur	11-02-1995	Y-Abstract
	WO	95/29691	A1	Georgia Tech Research Corporation	11-09-1995	
	WO	95/34538	A2	Univeristaire Instelling Antwerpen	12-21-1995	
	WO	01/89569	A1	Institut für Medizintechnologie Magdeburg GmbH Imtm	11-29-2001	Y-Abstract
	WO	2005/071073	A1	Point Therapeutics, Inc.	08-04-2005	

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		ANSORGE et al., CD26/dipeptidyl peptidase IV in lymphocyte growth regulation. Adv Exp Med Biol. 1997;421:127-40. Abstract Only.	
		BACHOVCHIN et al., Inhibition of IgA1 proteinases from Neisseria gonorrhoeae and Hemophilus influenzae by peptide prolyl boronic acids. J Biol Chem. 1990 Mar 5;265(7):3738-43.	
		BRISTOL et al., Thymocyte costimulating antigen is CD26 (dipeptidyl-peptidase IV). Costimulation of granulocyte, macrophage, and T lineage cell proliferation via CD26. J Immunol. 1992 Jul 15;149(2):367-72.	
		BRISTOL et al., Inhibition of CD26 enzyme activity with pro-boropro stimulates rat granulocyte/macrophage colony formation and thymocyte proliferation in vitro. Blood. 1995 Jun 15;85(12):3602-9.	
		COUTTS et al., Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides. J Med Chem. 1996 May 10;39(10):2087-94.	
		DEMUTH et al., Design of (omega-N-(O-acyl)hydroxy amid) aminodicarboxylic acid pyrrolidides as potent inhibitors of proline-specific peptidases. FEBS Lett. 1993 Mar 29;320(1):23-7.	
		FLEISCHER et al., Triggering of cytotoxic T lymphocytes and NK cells via the Tp103 pathway is dependent on the expression of the T cell receptor/CD3 complex. J Immunol. 1988 Aug 15;141(4):1103-7. Abstract Only.	
		FLENTKE et al., Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1556-9.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

[#] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

APPLICATION NO.:	10/616,694	ATTY. DOCKET NO.:	I0248.70023US00
FILING DATE:	July 9, 2003	CONFIRMATION NO.:	1643
APPLICANT:	Adams et al.		
GROUP ART UNIT:	1654	EXAMINER:	David Lukton

Sheet 3 of 4

	GÜNTHER et al., Solution structures of the DP IV (CD26) inhibitor Val-BoroPro determined by NMR spectroscopy. <i>Magn Reson Chem.</i> 1995;33:959-70.	
	GUTHEIL et al., Separation of L-Pro-DL-boroPro into its component diastereomers and kinetic analysis of their inhibition of dipeptidyl peptidase IV. A new method for the analysis of slow, tight-binding inhibition. <i>Biochemistry.</i> 1993 Aug 31;32(34):8723-31.	
	HEGEN et al., Function of dipeptidyl peptidase IV (CD26, Tp103) in transfected human T cells. <i>Cell Immunol.</i> 1993 Feb;146(2):249-60. Abstract Only.	
	HEGEN et al., Enzymatic activity of CD26 (dipeptidylpeptidase IV) is not required for its signalling function in T cells. <i>Immunobiology.</i> 1993 Dec;189(5):483-93. Abstract Only.	
	HEINS et al., Mechanism of proline-specific proteinases: (I) Substrate specificity of dipeptidyl peptidase IV from pig kidney and proline-specific endopeptidase from <i>Flavobacterium meningosepticum</i> . <i>Biochim Biophys Acta.</i> 1988 May 18;954(2):161-9. Abstract Only.	
	HILDEBRANDT et al., Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease. <i>Scand J Gastroenterol.</i> 2001 Oct;36(10):1067-72. Abstract Only.	
	HOFFMANN et al., Dipeptidyl peptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences. <i>FEBS Lett.</i> 1993 Dec 20;336(1):61-4.	
	KELLY et al., Immunosuppressive boronic acid dipeptides: correlation between conformation and activity. <i>J Am Chem Soc.</i> 1993;115:12637-8.	
	LOKSHINA et al., Proteolytic enzymes in human leukemic lymphoid cells. III. Aminopeptidases, angiotensin-converting enzyme, and its inhibitor in cells of different immunological phenotype. <i>Biochemistry (Mosc).</i> 1999 Apr;64(4):448-55. Abstract Only.	
	MATTESON et al., Synthesis and properties of pinanediol .alpha.-amido boronic esters. <i>Organometallics.</i> 1984;3(8):1284-8.	
	MITTRUCKER et al., The cytoplasmic tail of the T cell receptor zeta chain is required for signaling via CD26. <i>Eur J Immunol.</i> 1995 Jan;25(1):295-7. Abstract Only.	
	MORIMOTO et al., 1F7, a novel cell surface molecule, involved in helper function of CD4 cells. <i>J Immunol.</i> 1989 Dec 1;143(11):3430-9.	
	ORAVECZ et al., Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. <i>J Exp Med.</i> 1997 Dec 1;186(11):1865-72.	
	ROSENBLUM et al., Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. <i>Curr Opin Chem Biol.</i> 2003 Aug;7(4):496-504.	
	SUBRAMANYAM et al., Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness. <i>J Immunol.</i> 1993 Mar 15;150(6):2544-53.	
	SUDMEIER et al., Solution structures of active and inactive forms of the DP IV (CD26) inhibitor Pro-boroPro determined by NMR spectroscopy. <i>Biochemistry.</i> 1994 Oct 18;33(41):12427-38.	
	THOMPSON et al., Use of peptide aldehydes to generate transition-state analogs of elastase. <i>Biochemistry.</i> 1973 Jan 2;12(1):47-51.	
	UNDERWOOD et al., Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase. <i>J Biol Chem.</i> 1999 Nov 26;274(48):34053-8.	

EXAMINER:

DATE CONSIDERED:

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/616,694	ATTY. DOCKET NO.: I0248.70023US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: July 9, 2003	CONFIRMATION NO.: 1643
				APPLICANT: Adams et al.	
Sheet	4	of	4	GROUP ART UNIT: 1654	EXAMINER: David Lukton

		WATSON et al., Continuous proliferation of murine antigen-specific helper T lymphocytes in culture. J Exp Med. 1979 Dec 1;150(6):1510-9. Abstract Only.	
		ZHU et al., Expression of a novel dipeptidyl peptidase 8 (DPP8) transcript variant, DPP8-v3, in human testis. Asian J Androl. 2005 Sep;7(3):245-55. Abstract Only.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

[#] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.